Ergomed Aktie - WKN: A117XM

Ergomed team discuss new coronavirus project and 'transformational 2019'

Proactive London's Andrew Scott speaks to Ergomed PLC's (LON:ERGO) chief financial officer Richard Barfield and head of clinical development Dr Gordana Tonkovic.

https://www.youtube.com/watch?v=A7EFdzW6CfA&feature=emb_title  

Edison Group Coverage: Resilient global pharma services specialist

We are initiating coverage on specialist pharmaceutical services provider Ergomed. We believe it should prove relatively resilient during the COVID-19 crisis and has the fundamentals in place to execute its growth strategy. Ergomed announced impressive audited numbers for FY19, with revenue up 26% to £68.3m and EBITDA up 5.5x to £12.5m. The FY19 announcement is effectively Ergomed’s fourth profit upgrade for FY19 and a small beat on recently reset FY19 expectations. Ergomed trades at a discounted EV/EBITDA of 10.1x vs the contract research outsourcing (CRO) sector average of 11.5x (FY20). We value Ergomed at £186m or 399p/share. Ergomed’s strong organic growth is benefiting from a clear strategic focus on high growth pharma sectors, margin control and order book growth (up 15% to £125m in FY19, giving 90% visibility to 2020).

https://www.edisongroup.com/publication/...-services-specialist/26441  

Ergomed Gives Update On Clinical Development Programme For Namilumab ERGOMED PLC - ERGOMED ANNOUNCES SECOND COVID-19 CLINICAL STUDY * ERGOMED PLC - PROVIDING SUPPORT FOR A CLINICAL DEVELOPMENT PROGRAMME FOR NAMILUMAB FOR TREATMENT OF PATIENTS WITH RAPIDLY WORSENING COVID-19. * ERGOMED PLC - PROGRAMME IS BEING CONDUCTED AT HUMANITAS RESEARCH HOSPITALS IN BERGAMO AND MILAN, ITALY

https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/804416

UK's Izana Bioscience tests rheumatoid arthritis drug in COVID-19 patients "The compassionate use programme is led by Professor Carlo Selmi, Izana said, while research services are being provided by Ergomed ERGO.L. Japan's Takeda 4502.T has a strategic equity stake in Izana."

https://www.nasdaq.com/articles/...ug-in-covid-19-patients-2020-04-05

 

In a statement, Someit Sidhu, chief executive of Izana said: “Evidence suggests that anti GM-CSF therapy has the potential to change the way patients' immune systems respond to the virus, and therefore to reduce dangerous inflammation and support recovery."

The programme is being conducted at the Humanitas Research Hospitals in Bergamo and Milan.

Ergomed is already involved in a study at the Papa Giovanni XXIII Hospital in Bergamo into siltuximab, an approved rheumatoid arthritis option that targets the IL-6 cytokine, as a treatment for COVID-19 patients who develop serious respiratory complications.

https://www.proactiveinvestors.co.uk/companies/...atments-916661.html

 

Wir stehen wieder auf altem Hoch. Hoffen wir dass Ergomed neben dem finanziellen Verdienst aus der Krise auch Erfolg bei seinen Studien hat. Der Wert wird gerademal mit 240 Mio bewertet... dabei sind Sie mit führend - Konkurrent mit einem Vielfachen davon!!!  

Businesses do their bit as coronavirus pandemic pulls community together
https://www.proactiveinvestors.co.uk/companies/...ogether-918067.html  

Webinar Ergomed: Ensuring Continuity in Rare Disease Clinical Trials During the COVID-19 Crisis
https://www.youtube.com/watch?v=bZZYRZNs0Xo  

Von Ergomed begleitet Studie:  Siltuximab bei Covid-19

Zwischenergebnisse veröffentlicht

Die Zwischenergebnisse der Sisco-Studie sind vielversprechend: Insgesamt werden 25 Patienten mit nachgewiesener Covid-19-Infektion untersucht und mit Siltuximab behandelt. Die Studie ist eine einarmige Fall-Kontroll-Studie: Alle Patienten erhielten den Wirkstoff in einer Dosis von 11 mg / kg – diese wurde über eine Stunde infundiert. Nach Ermessen des Arztes folgte bei fünf Patienten eine zweite Dosis 48 bis 72 Stunden nach der ersten Gabe. Im Durchschnitt sind die Patienten 64 Jahre alt, 86 Prozent waren männlich. Zu den häufigsten Grunderkrankungen zählen Hypertonie (43 Prozent), Herzkreislauferkrankungen (19 Prozent) und Diabetes (24 Prozent). Die Beobachtungsdauer der Patienten betrug durchschnittlich acht Tage. Primäre Endpunkte der Studie sind die Verringerung der Notwendigkeit einer invasiven Beatmung, die Verkürzung der Zeit auf der Intensivstation und die Reduktion der 30-Tage-Mortalität.
Vorläufige Ergebnisse sind positiv

Bei 76 Prozent der Patienten gab es positive Ergebnisse: Sieben der 21 Patienten zeigten eine Verbesserung der Symptome, bei neun stabilisierte sich der Krankheitszustand. Die Konzentration von C-reaktivem Protein (CRP) nahm bei allen Teilnehmern ab. Dennoch kam es bei 24 Prozent zu einer Verschlechterung, ein Patient verstarb. In den kommenden drei bis vier Wochen sollen die Ergebnisse mit einer abgestimmten Fallkontrolle verglichen werden, in der nicht mit Siltuximab behandelt wurde. Zudem befinde sich Eusa Pharma in Gesprächen mit verschiedenen Zentren, um eine größer angelegte Studie starten zu können, erklärte der Hersteller.
https://www.apotheke-adhoc.de/nachrichten/detail/...unter-sars-cov-2/  

ERGOMED verliert wohl heute, weil REMDESIVIR von GILEAD (https://www.onvista.de/news/...folgsmeldung-bei-remdesivir-354132709) als COVID Medikament Hoffnung bringt.

Dabei muss man wissen, das ERGOMED nicht als Medikamentenentwickler sondern in den Studien als Dienstleister auftritt - sprich ERGOMED verdient - ohne RISIKO.

Eines ist sicher, Dienstleistungen im Pharmabereich werden nachgefragt und der Markt wächst nicht nur wegen COVID.

Hoffen wir das REMDESIVR anschlägt....!  

WEBINAR: Drug Repurposing for COVID-19. Ergomed’s experts GORDANA TONKOVIC and Sally Amanuel will share insights into how they are supporting collaboration between industry, academia and clinicians on the frontline of the fight against COVID-19.
 
For more information: https://lnkd.in/gtc9rrg  

Notice of AGM and Annual Report and Board Changes
https://www.investegate.co.uk/ergomed-plc--ergo-/...005150700069855M/  

Ergomed PLC (LON:ERGO) revealed that its pharmacovigilance division, PrimeVigilance, has signed a collaboration deal with Automation Anywhere, a leader in robotic process automation (RPA), and DataRobot, an enterprise artificial intelligence specialist, to accelerate its intelligent automation strategy.

https://www.proactiveinvestors.co.uk/companies/...trategy-919786.html  

Pharmaceutical industry services provider Ergomed said it had entered into a strategic collaboration with Automation Anywhere, to accelerate the company's intelligent automation strategy.

https://www.sharesmagazine.co.uk/news/market/...t-automation-strategy  

Ergomed PLC (LON:ERGO) revealed that its pharmacovigilance division, PrimeVigilance, has signed a collaboration deal with Automation Anywhere, a leader in robotic process automation (RPA), and DataRobot, an enterprise artificial intelligence specialist, to accelerate its intelligent automation strategy. AIM-listed Ergomed said PrimeVigilance had completed a proof of concept and will now implement a cloud software solution to automate specific pharmacovigilance processes. The company noted that the productivity gains made possible by working with Automation Anywhere and DataRobot are expected to deliver organic growth more efficiently with the automation of manual, repetitive processes.

https://www.proactiveinvestors.co.uk/companies/...-monday-919807.html

 

"he use of their technologies will enable clients to improve quality and consistency within safety databases, as well as productivity.  This collaboration is part of ERGOMED PLC’s wider strategy, transforming the relationship between our people and technology and benefiting both our clients and shareholders.

The full announcement is available here: "

https://www.ergomedplc.com/...e-leadership-in-intelligent-automation/  

Ergomed’s experts shared their insights into how they are supporting collaboration between industry, academia and clinicians on the frontline of the fight against COVID-19.

Topics covered in this webinar include:
• What is repurposing and why is it important for COVID-19
• Key factors in methodologies and approaches to repurposing, with a focus on clinical considerations and available regulatory pathways
• Collaboration and engagement of all stakeholders

https://www.youtube.com/watch?v=k9GNyLMnTXE  

ERGOMEd präsenitert bei  Jefferies 2020 Healthcare Conference:

http://wsw.com/webcast/jeff126/...m/webcast/jeff126/ergo.l/index.aspx  

5 Jun 2020
Dr. Elliot Brown, One of PrimeVigilance’s Founding Directors, Offers Valuable Support for COVID-19 Studies

Ergomed  is delighted to announce that Dr. Elliot Brown, one of the original founders of PrimeVigilance, has offered his deep expertise and time to help with the evaluation and interpretation of safety data from clinical studies in Covid-19 as a consultant.

Dr. Brown has worked for over 30 years as a drug safety and risk management specialist, holding senior positions in the pharmaceutical industry and as an EU regulator and subsequently acting as a consultant to many companies and government regulatory bodies. Until recently he was an honorary safety adviser to the World Health Organization (WHO), and he is currently Associate Editor of the International Journal of Risk and Safety in Medicine.

Dr.Brown says: “I am really pleased to have this opportunity to be of some help during the pandemic by supporting PrimeVigilance and Ergomed in their valuable work on clinical trials involving COVID-19.”

Ergomed is very appreciative of Dr. Brown’s offer to share his wealth of global drug safety experience with us and our clients, helping to bring success in the fight against COVID-19.

https://www.ergomedplc.com/...-valuable-support-for-covid-19-studies/  

PrimeVigilance COVID-19 Webinar: How to Adapt Hosting, Conduction of Remote Audits and Inspections

https://www.ergomedplc.com/...ction-of-remote-audits-and-inspections/  

Ergomed plc - Annual General Meeting Statement
https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/827003

Guildford, UK - 10 June 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the following update from Dr Miroslav Reljanović, Executive Chairman, in advance of the Company's closed Annual General Meeting ('AGM') to be held this morning at 9.30am:

"Ergomed had a good first quarter, with solid overall growth in revenue. Following the outbreak of COVID-19 in March 2020, the Company has successfully transferred to a fully remote working operation with minimal disruption and no redundancies or furloughed staff.  

Edison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
https://www.investegate.co.uk/...-ergomed--ergo-/20200610134258EXYVV/

.... im Juli kommt es .....  

ERGOMED @ PCMG Live 2020
https://www.ergomedplc.com/event/pcmg-live-2020/
https://www.pcmg.org.uk/  

.. hat hier den Niemand ERGOMED auf dem RADAR ;)

Ergomed says full-year earnings to be “materially ahead of market expectations”

https://www.proactiveinvestors.co.uk/companies/...tations-924679.html  

Diversified services offering proves resilient

" Strong H120 sales and a record order book at 30 June 2020 should see Ergomed carry its strong momentum into 2020 and beyond. "

https://www.edisongroup.com/publication/...ing-proves-resilient/27339  

Ergomed reports on 'excellent' first half

https://www.sharecast.com/news/aim-bulletin/...rst-half--7581640.html